Once I start taking Deuterocolexitinib/Sondido, can I stop taking it?

Deucravacitinib is a new generation of oral small molecule immunomodulator that has attracted worldwide attention in recent years. It is a highly selective tyrosine kinase 2 (TYK2) inhibitor, which is different from traditional JAK inhibitors. By binding to the TYK2 regulatory domain, it blocks multiple key inflammatory signaling pathways, especially IL-23, IL-12 and type I interferon signals related to psoriasis pathology. It is this mechanism of action that enables it to demonstrate good efficacy and tolerability in the field of psoriasis treatment.

Currently, deuterated colexitinib is primarily approved for use in adults with moderate to severe plaque psoriasis, particularly those who require systemic therapy or phototherapy. Psoriasis is not only an erythematous and scaly disease on the skin surface, but may also be related to multi-system problems such as arthritis, metabolic syndrome, and cardiovascular disease. Therefore, timely and standardized systemic treatment is particularly important. As an oral drug, deuterated colexitinib provides patients with a more convenient option compared to injectable biologics.

In actual clinical applications, deuterated colexitinib is regarded as a balanced option between traditional systemic treatments (such as methotrexate, cyclosporine) and new biological agents. It can not only significantly improve the skin lesion clearance rate, but also improve the patient's quality of life, and shows good safety in long-term use. Compared with some JAK inhibitors, its adverse effects on hematology and metabolism are milder, and it also reduces excessive concerns about liver and kidney function.

It is worth mentioning that the global research and development of deuterated colexitinib is not limited to psoriasis, but is also exploring its potential role in immune-related diseases such as systemic lupus erythematosus and inflammatory bowel disease. However, currently in China and most countries, the approved indications are mainly concentrated in adult patients with psoriasis.

Reference materials:https://go.drugbank.com/drugs/DB16650